NR4A1 and breast cancer: Hormone receptor positivity was numerically more common in HER2-low breast cancer than in the other two groups (83.2% in HER2-low vs 72.7% in HER2-zero vs 77.9% in HER2-positive, p = 0.293; Supplementary Figure S2).